-
公开(公告)号：US20230116837A1
公开(公告)日：2023-04-13
申请号：US17689706
申请日：2022-03-08
Applicant: David Alan Heldreth, JR.
Inventor： David Alan Heldreth, JR.
IPC: A01G22/15 , A61K36/185 , A23L29/00 , A23L2/52 , A24B15/16 , A24B15/167 , C12G3/04 , A01C7/00 , A01D45/06
Abstract: This present invention is directed to a method for the production and use of the leaf and/or leaves and/or stem(s) and/or stalk(s) of plants of the cannabis species for animal, microbial, bacteria, fungi or human consumption as a food, supplement, medicine, beverage.
-
2.发明申请
公开(公告)号：US20180279611A1
公开(公告)日：2018-10-04
申请号：US15943703
申请日：2018-04-03
Applicant: David Alan Heldreth, JR.
Inventor： David Alan Heldreth, JR.
Abstract: The invention involves the use of a combination of s-abscisic acid (S-ABA), methyl jasmonate (MJ), glucose, sucrose and fructose to raise the level of cannabinoids and terpenes (flavor and scent molecules) in the Cannabis Sativa plant.
-
公开(公告)号：US20240325344A1
公开(公告)日：2024-10-03
申请号：US18625194
申请日：2024-04-02
Applicant: David Alan Heldreth, JR.
Inventor： David Alan Heldreth, JR.
IPC: A61K31/352 , A61K31/015 , A61K31/05 , A61K31/135 , A61K31/164 , A61K31/165 , A61K31/404 , A61K31/4045 , A61K31/473 , A61K31/4741 , A61K31/48 , A61K31/675 , A61K31/704 , A61K33/06 , A61K33/30 , A61K36/68 , A61K36/77
CPC classification number: A61K31/352 , A61K31/015 , A61K31/05 , A61K31/135 , A61K31/164 , A61K31/165 , A61K31/404 , A61K31/4045 , A61K31/473 , A61K31/4741 , A61K31/48 , A61K31/675 , A61K31/704 , A61K33/06 , A61K33/30 , A61K36/68 , A61K36/77
Abstract: The invention involves the use of formulations of allosteric modulators of primarily 5ht2/tht1, CB1 and GLP-1 serotonin transporter, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7 and other receptors, in combination with phenethylamines, tryptamines, ibogaloids and other compounds; to treat or reduce symptoms of ingestion of drugs such as Cannabis or 5ht2a agonists. The method of delivery/formulation selected from: Beverage (soda, water, tea, coffee, or other), Candy (gum, gummy, chocolate, hard candy, taffy, or other), Food, smoking, vaping, e-cigarette, vape-pen, bong, vaporizer, tab, geltab, blotter, sublingual strip.
-
公开(公告)号：US20240325342A1
公开(公告)日：2024-10-03
申请号：US18625181
申请日：2024-04-02
Applicant: David Alan Heldreth, JR.
Inventor： David Alan Heldreth, JR.
IPC: A61K31/352 , A61K31/015 , A61K31/05 , A61K31/135 , A61K31/164 , A61K31/165 , A61K31/404 , A61K31/4045 , A61K31/473 , A61K31/4741 , A61K31/48 , A61K31/675 , A61K31/704 , A61K33/06 , A61K33/30 , A61K36/68 , A61K36/77
CPC classification number: A61K31/352 , A61K31/015 , A61K31/05 , A61K31/135 , A61K31/164 , A61K31/165 , A61K31/404 , A61K31/4045 , A61K31/473 , A61K31/4741 , A61K31/48 , A61K31/675 , A61K31/704 , A61K33/06 , A61K33/30 , A61K36/68 , A61K36/77
Abstract: The invention involves the use of formulations of allosteric modulators of primarily 5ht2/5ht1, opiate or SERT serotonin transporter, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7, dopamine, GLP, and other receptors/systems, in combination with phenethylamines, tryptamines, ibogaloids as well as vaccines, antibodies and other compounds; to treat opiate dependency (addiction). Wherein opiate means, any opiate compound/mixture/drug, including, but not limited to synthetic, semisynthetic, natural, such as but not limited to opium, morphine, heroin, codeine, oxycodone, fentanyl, methadone, or other.
-
公开(公告)号：US20220265601A1
公开(公告)日：2022-08-25
申请号：US17667147
申请日：2022-02-08
Applicant: David Alan Heldreth, JR.
Inventor： David Alan Heldreth, JR.
IPC: A61K31/352 , A61K31/05 , A61K31/48 , A61K31/4045 , A61K31/675 , A61K31/404 , A61K33/30 , A61K33/06 , A61K31/015 , A61K31/135 , A61K36/68 , A61K31/473 , A61K31/164 , A61K31/165 , A61K31/4741 , A61K31/704 , A61K36/77
Abstract: The invention involves the use of formulations of positive, negative, inverse agonist, or neutral allosteric modulators of receptors such as, but not limited to: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht5, 5ht6, 5ht7, dopamine receptors (D1, D2, D3, D4, D5), adrenergic receptors (α1A, α1B, α2A, α2B, α2C, β1, β2), serotonin transporter (SERT), DA transporter (DAT), norepinephrine transporter (NET), imidazoline1 receptor (I1), Sigma receptors (σ1, σ2), delta opioid receptor (DOR), kappa opioid receptor (KOR), mu opioid receptor (MOR), muscarinic receptors (M1, M2, M3, M4, M5), histamine receptors (H1, H2), calcium ion channel (Ca+) and N-methyl D-aspartate (NMDA) glutamate receptor; alone or in combination with items such as, but not limited to: cannabinoids, terpenes, flavonoids, minerals, psychedelic and psychoactive compounds such as, but not limited to 5ht2a receptor agonists or other compounds; for medical, recreational, religious, research and other uses.
-
公开(公告)号：US20240398751A1
公开(公告)日：2024-12-05
申请号：US18625137
申请日：2024-04-02
Applicant: David Alan Heldreth, JR.
Inventor： David Alan Heldreth, JR.
IPC: A61K31/352 , A61K31/015 , A61K31/05 , A61K31/135 , A61K31/164 , A61K31/165 , A61K31/404 , A61K31/4045 , A61K31/473 , A61K31/4741 , A61K31/48 , A61K31/675 , A61K31/704 , A61K33/06 , A61K33/30 , A61K36/68 , A61K36/77
Abstract: The invention involves the use of formulations of allosteric modulators of primarily 5ht2a/5ht1a, opiate or SERT serotonin transporter, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7, dopamine, GLP, and other receptors/systems, in combination with phenethylamines, tryptamines, ibogaloids as well as vaccines, antibodies and other compounds; to treat stimulant dependency (addiction).
-
公开(公告)号：US20240398750A1
公开(公告)日：2024-12-05
申请号：US18625131
申请日：2024-04-02
Applicant: David Alan Heldreth, JR.
Inventor： David Alan Heldreth, JR.
IPC: A61K31/352 , A61K31/015 , A61K31/05 , A61K31/135 , A61K31/164 , A61K31/165 , A61K31/404 , A61K31/4045 , A61K31/473 , A61K31/4741 , A61K31/48 , A61K31/675 , A61K31/704 , A61K33/06 , A61K33/30 , A61K36/68 , A61K36/77
Abstract: The invention involves the use of formulations of allosteric modulators of primarily 5ht2/5ht1, glutamate or SERT serotonin transporter, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7, dopamine, GLP, and other receptors/systems, in combination with phenethylamines, tryptamines, ibogaloids as well as vaccines, antibodies and other compounds; to treat or reduce symptoms of anxiety, depression, attention deficiency (ADD), attention deficient hyperactivity (ADHD), obsessive compulsive (OCD), bipolar disorder, and related disorders/conditions.
-
公开(公告)号：US20240299341A1
公开(公告)日：2024-09-12
申请号：US18616121
申请日：2024-03-25
Applicant: David Alan Heldreth, JR.
Inventor： David Alan Heldreth, JR.
IPC: A61K31/352 , A61K31/015 , A61K31/05 , A61K31/135 , A61K31/164 , A61K31/165 , A61K31/404 , A61K31/4045 , A61K31/473 , A61K31/4741 , A61K31/48 , A61K31/675 , A61K31/704 , A61K33/06 , A61K33/30 , A61K36/68 , A61K36/77
CPC classification number: A61K31/352 , A61K31/015 , A61K31/05 , A61K31/135 , A61K31/164 , A61K31/165 , A61K31/404 , A61K31/4045 , A61K31/473 , A61K31/4741 , A61K31/48 , A61K31/675 , A61K31/704 , A61K33/06 , A61K33/30 , A61K36/68 , A61K36/77
Abstract: The invention involves the use of formulations of positive, negative or other allosteric modulators of primarily 5ht2a receptors, but also those of: 5ht1a/b/c/d, 5ht2b/c, 5ht3, 5ht4, 5ht7, and other receptors and systems, in combination with phenethylamines and other compounds; to treat nicotine dependency (addiction) such as tobacco-use (smoking, vaping, sublingual, oral) and/or tobacco smoking cessation.
-
公开(公告)号：US20240269107A1
公开(公告)日：2024-08-15
申请号：US18616089
申请日：2024-03-25
Applicant: David Alan Heldreth, JR.
Inventor： David Alan Heldreth, JR.
IPC: A61K31/352 , A61K31/015 , A61K31/05 , A61K31/135 , A61K31/164 , A61K31/165 , A61K31/404 , A61K31/4045 , A61K31/473 , A61K31/4741 , A61K31/48 , A61K31/675 , A61K31/704 , A61K33/06 , A61K33/30 , A61K36/68 , A61K36/77
CPC classification number: A61K31/352 , A61K31/015 , A61K31/05 , A61K31/135 , A61K31/164 , A61K31/165 , A61K31/404 , A61K31/4045 , A61K31/473 , A61K31/4741 , A61K31/48 , A61K31/675 , A61K31/704 , A61K33/06 , A61K33/30 , A61K36/68 , A61K36/77
Abstract: The invention involves the use of formulations of positive, negative or other allosteric modulators of primarily 5ht2a receptors, but also those of: 5ht1a/b/c/d, 5ht2b/c, 5ht3, 5ht4, 5ht7, and other receptors in combination with phenethylamines and other compounds; to treat brain cancer such as glioma(s) and/or glioblastoma(s).
-
公开(公告)号：US20240261252A1
公开(公告)日：2024-08-08
申请号：US18581790
申请日：2024-02-20
Applicant: David Alan Heldreth, JR.
Inventor： David Alan Heldreth, JR.
IPC: A61K31/352 , A61K31/015 , A61K31/05 , A61K31/135 , A61K31/164 , A61K31/165 , A61K31/404 , A61K31/4045 , A61K31/473 , A61K31/4741 , A61K31/48 , A61K31/675 , A61K31/704 , A61K33/06 , A61K33/30 , A61K36/68 , A61K36/77
CPC classification number: A61K31/352 , A61K31/015 , A61K31/05 , A61K31/135 , A61K31/164 , A61K31/165 , A61K31/404 , A61K31/4045 , A61K31/473 , A61K31/4741 , A61K31/48 , A61K31/675 , A61K31/704 , A61K33/06 , A61K33/30 , A61K36/68 , A61K36/77
Abstract: The invention involves the use of formulations of positive, negative, inverse agonist, or neutral allosteric modulators of receptors such as, but not limited to: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht5, 5ht6, 5ht7, dopamine receptors (D1, D2, D3, D4, D5), adrenergic receptors (α1A, α1B, α2A, α2B, α2C, β1, β2), serotonin transporter (SERT), DA transporter (DAT), norepinephrine transporter (NET), imidazolinel receptor (I1), Sigma receptors (σ1, σ2), delta opioid receptor (DOR), kappa opioid receptor (KOR), mu opioid receptor (MOR), muscarinic receptors (M1, M2, M3, M4, M5), histamine receptors (H1, H2), calcium ion channel (Ca+) and N-methyl D-aspartate (NMDA) glutamate receptor; alone or in combination with items such as, but not limited to: cannabinoids, terpenes, flavonoids, minerals, psychedelic and psychoactive compounds such as, but not limited to 5ht2a receptor agonists or other compounds; for medical, recreational, religious, research and other uses.
